London, UK, 27th January 2015 / Sciad Newswire / Biotech and Money London, 3-4 February 2015: Biotech and Money, the high level UK life science congress helping organisations to find funding, investment and partnerships, is pleased to announce the addition of a panel session hosted by the Biomedical Catalyst (BMC), which will allow delegates the opportunity to meet with representatives of the Awards body. 

Representatives from Innovate UK and the Biomedical Catalyst, along with Ipsos MORI will examine the BMC process as well as its economic impact on the funding landscape and invite discussion on what delegates would like to see as improvements to the scheme. 

According to Elaine Evans, Lead Technologist, Medicines and Healthcare, Innovate UK who will lead the Q&A and review session:

‘With a backdrop to building the case for an extension of this scheme into the new government, building in any changes based on learning from the first 3 years of the programme (which ends in June 2015) will be invaluable.  From our point of view, getting feedback from Investors on their perceptions of any impacts of the Biomedical Catalyst on the funding landscape since it went live in June 2012 would be particularly useful.’

Neil Darkes, Co-CEO of Biotech and Money added: “We’re delighted to be able to provide the Biomedical Catalyst a platform at this congress to aid in their stakeholder engagement plans. We look forward to what I’m sure will be an engaging and interactive debate” 

The panel session will take place from 2.00pm on the 3rd February, day one of the Biotech and Money London congress.


For more information see: or contact:

Neil Darkes, Biotech and Money; t +44 (0) 203 574 4619

Deborah Cockerill, Media Relations, Sciad Communications:

e.; m. +44 (0)7930 317729

Biotech and Money London 2015 is a two-day congress providing the education, strategies and solutions executives need to enable more effective funding, investment, business planning and partnering within your business. These 2-days will change your company’s funding, investment and partnering outlook in 2015. It’s where life science meets money, investors uncover innovation and pharma seek partners. Other sessions that are outlined at the congress includes best practice and education on tech transfer, commercialisation, translational funding, follow-on and growth capital, corporate venture, Licensing and Partnerships, IPO and M&A. Plus discussions on emerging mega therapeutics areas such as Precision Medicine, Immuno-Oncology, Digital Health and Cell Therapy plus Reimbursement.

About Biomedical Catalyst: The Biomedical Catalyst is a funding programme jointly operated with Innovate UK (formerly the Technology Strategy Board – TSB) providing responsive and effective support for the best translational life science opportunities arising in the UK. Grants are available to UK academics and small and medium enterprises (SMEs) seeking to move their research more quickly from discovery to commercialisation.


Got an innovation you need bringing to life?

We’d love to hear from you! Head to our contact page to start a conversation.

Photo of Paul Coates